HC Wainwright & Co. Reiterates Buy on Mainz Biomed, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen reiterates a Buy rating on Mainz Biomed (NASDAQ:MYNZ) and maintains a $10 price target.
June 01, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Yi Chen reiterates a Buy rating on Mainz Biomed and maintains a $10 price target.
The news of HC Wainwright & Co. analyst Yi Chen reiterating a Buy rating on Mainz Biomed and maintaining a $10 price target is positive for the company's stock. This reaffirms the analyst's confidence in the company's potential and could lead to increased investor interest, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100